Replies to post #1581 on Cardiff Oncology, Inc. (CRDF)

[Viewmont]

This should help move the stock a bit. Trovagene to Present New Clinical Data for Onvansertib in Metastatic Castration-Resistant Prostate Cancer at ASCO Genitourinary Cancers Symposium
PR Newswire PR Newswire•February 5, 2020
SAN DIEGO, Feb. 5, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, oncology therapeutics company developing onvansertib for the treatment of various cancers including prostate, colorectal, and leukemia, today announced that a poster featuring efficacy data from its Phase 2 study in metastatic castrate-resistant prostate cancer (mCRPC), will be presented on Thursday, February 13th, 2020 at the American Society for Clinical Oncology (ASCO) 2020 Genitourinary Cancers Symposium in San Francisco.